Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

JAK inhibition may help manage autoimmune conditions in Down syndrome.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

A cancer patient's hair became permanently curly after treatment with nivolumab.

Rituximab may cause skin issues, but baricitinib can help improve them.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.